Dimension Fund III | 2026 VC Fund

Dimension

cb Email

Status

ACTIVE

Global HQ

New York, United States

Countries of investment

United States
United Kingdom
Canada
Switzerland
Israel
Germany
Netherlands

Investment stages

Seed
Series A
Series B
Series C
Growth

Industries

Artificial Intelligence
Machine Learning
Biotechnology
Life Sciences
Drug Discovery
Advanced Manufacturing
Computational Biology
TechBio
Deep Tech
Enterprise Software
Healthcare

About
Dimension is a New York-based venture capital firm focused on backing companies at the intersection of biotechnology and computing. Their focus spans AI, machine learning, life sciences, biotech, and drug discovery across the United States, United Kingdom, Canada, Switzerland, Israel, Germany, and Netherlands. The firm supports frontier tech founders from seed through growth stages.

Min check size: $1M
Max check size: $30M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Dimension is a seed to growth stage multistage venture capital firm deploying capital across artificial intelligence, machine learning, biotechnology, life sciences, drug discovery, advanced manufacturing, and computational biology sectors. They invest as high-conviction lead investors with concentrated positions (roughly 20 per fund) in companies at the frontiers of science and compute, working closely with founders as core architects. The firm differentiates itself through research-oriented approach led by former Lux Capital and Obvious Ventures partners, with $850M AUM across two funds and unique technical-life sciences bridging capabilities.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Founded in 2023 by Zavain Dar and Adam Goulburn (both former General Partners at Lux Capital) and Nan Li (former Managing Director at Obvious Ventures). Team of 9 including 4 partners across New York and San Francisco. Manages $1.65B AUM across three funds: Fund I ($350M, 2022), Fund II ($500M oversubscribed 2024), Fund III ($800M closed 2026). Portfolio includes Chai Discovery ($3.8B), Enveda Biosciences, New Limit, Monte Rosa (public), and Coefficient Bio (acquired by Anthropic for $400M).